ClinicalTrials.gg
CompletedNCT07320157HPV-EducationUpdated Jul 30, 2026

The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake

An interventional study of Online Education Intervention Group and Contral Group in HPV (Human Papillomavirus)-Associated and HPV Immunization Status, sponsored by Ufuk University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Ufuk University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Type of Study: This study was planned to be an observational study.

Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question[s] it aims to answer [is/are]:

H1: There is a difference in the mean Human Papillomavirus (HPV) Knowledge Scale score between the intervention group women who participated in Human Papillomavirus (HPV) education and the control group women.

H2: There is a difference between the intervention group women and the control group women in terms of their participation in HPV screening tests.

H2: There is a difference between the intervention group women and the control group women in terms of their HPV vaccination status.

Participants Participants will be assigned to a control and intervention group. Online training will be provided to the intervention group, and the results of the training will be reported.

02

Conditions studied

  • HPV (Human Papillomavirus)-Associated
  • HPV Immunization Status

Keywords

  • HPV
  • WOMEN
  • HEALTH
  • VACCİNE
03

In context

Papillomavirus Infections

576 studies on the registry are indexed under Papillomavirus Infections; 132 are open to participants now.

This study's enrollment of 59 is below the median of 235 across 402 interventional studies indexed under Papillomavirus Infections.

Browse Papillomavirus Infections studies →

Lead sponsor

Ufuk University is the lead sponsor of 41 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being female
  • Women aged 18-35 years
  • Ability to speak and understand Turkish at a level sufficient to communicate with the researcher
  • Having the technical equipment necessary to participate in a video interview
  • No diagnosis of HPV positivity
  • Not having received the HPV vaccine
  • Not having undergone HPV DNA/Pap smear testing in the past 5 years
  • No diagnosis of cervical cancer
  • Voluntary willingness to participate in the study
  • No diagnosis of a psychiatric disorder

Exclusion criteria

Exclusion Criteria:

  • Being male
  • Having severe physical or cognitive impairments that prevent completing the questionnaire
  • Being under 18 years of age or over 35 years of age
  • Inability to speak or understand Turkish
  • Lack of technical equipment to participate in a video interview
  • Having a diagnosis of HPV positivity
  • Having received the HPV vaccine
  • Having undergone HPV DNA/Pap smear testing in the past 5 years
  • Having a diagnosis of cervical cancer
  • Having a diagnosed psychiatric disorder

Not agreeing to participate in the study

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Online Education Intervention Group

    An online training session will be scheduled for the intervention group. The training will consist of two 40-minute session. After the online training, the training materials will be shared with the group. One week after the training, an informational brochure prepared on the topic will be sent to the intervention group via WhatsApp as a reminder, and any questions they may have will be answered. Two weeks after delivering the brochure, the questionnaire/scale forms will be administered to both groups as the first follow-up. Eight weeks after the first follow-up, the same forms will be administered again as the post-test. The WhatsApp group will remain open and interaction will be allowed throughout the research period.

    Behavioral: Online Education Intervention Group · Other: Contral Group

Interventions

  • BehavioralOnline Education Intervention Group

    An online training session will be scheduled for the intervention group. The training will consist of two 40-minute session. After the online training, the training materials will be shared with the group. One week after the training, an informational brochure prepared on the topic will be sent to the intervention group via WhatsApp as a reminder, and any questions they may have will be answered. Two weeks after delivering the brochure, the questionnaire/scale forms will be administered to both groups as the first follow-up. Eight weeks after the first follow-up, the same forms will be administered again as the post-test. The WhatsApp group will remain open and interaction will be allowed throughout the research period.

  • OtherContral Group

    No intervention will be applied to the control group. Following the completion of the study, the brochure prepared on the topic will be sent to them via WhatsApp.

06

What researchers measure

Primary outcomes

  1. Change in HPV Knowledge Score

    Change in participants' HPV Knowledge Scale scores measured at baseline, first follow-up, and final follow-up. The measure evaluates the effect of the online education and brochure intervention compared to the control group.

    Time frame: Baseline (before intervention), 2 weeks after brochure delivery (first follow-up), and 8 weeks after the first follow-up (final follow-up)

Secondary outcomes

  1. Sustained HPV Knowledge Score (Knowledge Retention)

    Final follow-up (8 weeks after the first follow-up)

    Time frame: Knowledge retention will be assessed by comparing HPV Knowledge Scale scores between groups at the final follow-up. Higher scores indicate better long-term retention of information provided by the intervention.

07

Study locations

1 site
  • UfUK UNIVERSITY
    Ankara, Ankara 06000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Due to privacy and confidentiality concerns of the participants, individual participant data will not be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07320157
Lead sponsor
Ufuk University
Responsible party
Gizem Bilmez (Principal Investigator, Ufuk University) — Principal investigator
First posted
Jan 6, 2026
Start date
Jan 9, 2026
Primary completion
Jan 23, 2026
Completion
Apr 23, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion